Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07667413 · ClinicalTrials.gov registry record · Phase 1
Topical TOR-582 Treatment of Epistaxis in HHT
A Phase 1 study, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT07667413 is a Phase 1 study that is actively recruiting participants, run by Columbia University. The registered enrollment target is 27 participants.
The verdict
NCT07667413, a Phase 1 study, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical procedures, and reduced quality of life. This study is testing a new nasal ointment called TOR-582, which contains sirolimus, to determine whether it can be used safely when applied inside the nose. Adults with HHT and frequent nosebleeds will be invited to participate. Participants will first complete one week of observation without treatment, followed by up to 12 weeks of applying the study ointment inside each nostril twice daily. Different participants will receive different strengths of the ointment so researchers can identify the safest dose. During the study, participants will attend study visits, complete questionnaires about their nosebleeds and quality of life, keep a daily nosebleed diary, undergo nasal examinations, and have blood tests to monitor safety and medication levels. The information gained from this study will help determine whether this topical treatment can be safely studied further and will support the development of a new, less invasive option for managing nosebleeds in people with HHT.
Interventions
- DRUG Topical sirolimus ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07667413
The ClinicalTrials.gov registry entry for NCT07667413 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topical sirolimus ointment is the first listed.
NCT07667413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07667413 about?
NCT07667413 is a clinical study titled "Topical TOR-582 Treatment of Epistaxis in HHT". People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical procedures, and reduced quality of life. This study is testing a new nasal ointment called TOR-582, which contains sirolimus, to determine w...
What is the current status of trial NCT07667413?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2026-07. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07667413?
The interventions under investigation include: Topical sirolimus ointment (DRUG).
Who is sponsoring clinical trial NCT07667413?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.